InsiderTrades

Form 4 for IBRX ImmunityBio, Inc.

Accepted 2024-02-06 00:00:00 ET · period of report 2024-02-05 · accession 0001326110-24-000018 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-02-06 2024-02-05 IBRX Adcock Richard CEO, Pres, Dir F - Tax $4.04 -43.2K 243.1K -15% -$174.4K
D 2024-02-06 2024-02-05 IBRX Adcock Richard CEO, Pres, Dir M - OptEx $0.00 +83.3K 286.3K +41% $0
D 2024-02-06 2024-02-05 IBRX Adcock Richard CEO, Pres, Dir M - OptEx $0.00 -83.3K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-05 F D 43,165 $4.04 243,138 D — —
2 Common Common Stock 2024-02-05 M A 83,334 $0.00 286,303 D — —
3 Derivative Restricted Stock Units 2024-02-05 M D 83,334 $0.00 0 D — · — to — 83,334 Common Stock (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. (F2) Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award vested in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares vested on the third anniversary of the vesting commencement date, such that all shares were vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award was February 5, 2021.